HC Wainwright Issues Positive Forecast for Niagen Bioscience (NASDAQ:NAGE) Stock Price

Key Points

• HC Wainwright has raised its price target for Niagen Bioscience from $11.00 to $12.00, indicating a potential upside of 23.33%.
• Other analysts, including Roth Capital, have also given buy ratings, with a notable price target increase to $23.00.
• The company's recent earnings report showed a profit of $0.04 EPS, surpassing expectations, with revenue of $31.12 million.

Niagen Bioscience (NASDAQ:NAGE - Get Free Report) had its price target hoisted by HC Wainwright from $11.00 to $12.00 in a research report issued on Monday,Benzinga reports. The firm currently has a "buy" rating on the stock. HC Wainwright's target price indicates a potential upside of 21.21% from the company's previous close. HC Wainwright also issued estimates for Niagen Bioscience's Q3 2025 earnings at $0.02 EPS, Q4 2025 earnings at $0.02 EPS, FY2025 earnings at $0.15 EPS, Q1 2026 earnings at $0.07 EPS, Q2 2026 earnings at $0.09 EPS, Q3 2026 earnings at $0.11 EPS, Q4 2026 earnings at $0.13 EPS and FY2026 earnings at $0.40 EPS.

NAGE has been the topic of several other reports. Roth Capital reiterated a "buy" rating and issued a $23.00 price objective (up from $10.00) on shares of Niagen Bioscience in a report on Friday, June 6th. Wall Street Zen downgraded shares of Niagen Bioscience from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 2nd. Finally, Canaccord Genuity Group upped their price target on shares of Niagen Bioscience from $13.00 to $16.00 and gave the company a "buy" rating in a research note on Tuesday, June 10th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, Niagen Bioscience has a consensus rating of "Buy" and a consensus price target of $13.42.

Niagen Bioscience Trading Up 2.0%

Shares of NASDAQ:NAGE traded up $0.19 on Monday, hitting $9.90. The company had a trading volume of 501,081 shares, compared to its average volume of 948,855. Niagen Bioscience has a 1-year low of $3.10 and a 1-year high of $14.69. The stock has a market cap of $789.53 million, a price-to-earnings ratio of 47.15 and a beta of 2.12. The stock has a 50 day moving average price of $11.63 and a 200 day moving average price of $8.41.

Niagen Bioscience (NASDAQ:NAGE - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported $0.04 EPS for the quarter, beating the consensus estimate of $0.02 by $0.02. Niagen Bioscience had a net margin of 15.24% and a return on equity of 23.12%. The firm had revenue of $31.12 million for the quarter, compared to the consensus estimate of $28.55 million.

Institutional Investors Weigh In On Niagen Bioscience

Several institutional investors and hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC lifted its position in Niagen Bioscience by 0.5% during the fourth quarter. Geode Capital Management LLC now owns 1,154,778 shares of the company's stock worth $6,128,000 after purchasing an additional 5,186 shares during the period. D. E. Shaw & Co. Inc. lifted its position in Niagen Bioscience by 1,785.9% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,011,290 shares of the company's stock worth $5,365,000 after purchasing an additional 957,665 shares during the period. Renaissance Technologies LLC lifted its position in Niagen Bioscience by 68.0% during the fourth quarter. Renaissance Technologies LLC now owns 712,788 shares of the company's stock worth $3,781,000 after purchasing an additional 288,588 shares during the period. Northern Trust Corp lifted its position in Niagen Bioscience by 13.8% during the fourth quarter. Northern Trust Corp now owns 429,873 shares of the company's stock worth $2,280,000 after purchasing an additional 52,170 shares during the period. Finally, JPMorgan Chase & Co. lifted its position in Niagen Bioscience by 2.8% during the fourth quarter. JPMorgan Chase & Co. now owns 341,221 shares of the company's stock worth $1,810,000 after purchasing an additional 9,305 shares during the period. Institutional investors own 15.41% of the company's stock.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.